ArticleEndocrine, metabolic & immune disorders drug targets2026
Mendelian Randomization Analysis of Psoriasis and Multiparameter Renal Function Trajectories.
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWhile observational studies suggest that psoriasis may increase the risk of renal impairment, evidence supporting a causal relationship remains inconclusive. This Mendelian randomization (MR) study systematically investigates the genetic causality between psoriasis and multidimensional renal function trajectories, encompassing both static measures and dynamic progression patterns.
methodsWe utilized genetic variants associated with psoriasis identified in a Finnish population- based genome-wide study of 373,338 participants. Using a two-sample MR framework, we examined potential causal relationships across six kidney-related outcomes: (1) estimated glomerular filtration rate (eGFR), (2) albuminuria, (3) chronic kidney disease stages G3-G5 (CKD G3-G5), (4) need for dialysis, (5) accelerated progression to CKD (CKDi25), and (6) rapid deterioration in renal function (Rapid3). To ensure robustness, we applied MR-PRESSO for outlier correction and performed inverse-variance weighted (IVW) analyses under a random-effects model as the primary method, complemented by comprehensive sensitivity analyses.
resultsGenetic liability to psoriasis showed no causal association with any of the following renal outcome: eGFR (β = -0.0005, P = 0.393), albuminuria (OR = 0.992, P = 0.819), CKD G3-G5 (OR = 1.012, P = 0.520), dialysis (OR = 0.940, P = 0.377), CKDi25 (OR = 1.013, P = 0.527), or Rapid3 (OR = 1.005, P = 0.728). No evidence of horizontal pleiotropy was detected. DISCUSSION: Although prior observational studies have linked psoriasis to impaired kidney function, these associations are likely confounded by factors, such as nephrotoxic drug use (e.g., cyclosporine), metabolic comorbidities, or medical surveillance bias. In contrast, this MR study focused exclusively on genetic susceptibility to psoriasis, effectively avoiding such confounding factors. Our findings provide robust genetic evidence that psoriasis itself does not causally affect kidney function, as supported by the lack of significant associations across multiple renal endpoints. Moreover, genetic overlap between psoriasis and kidney disease risk appears minimal, reinforcing the notion that psoriasis is not an independent driver of renal damage. Clinically, screening should emphasize traditional risk factors, such as hypertension and diabetes. In psoriasis patients without these risk factors, frequent long-term kidney monitoring lacks a genetic rationale, which could optimize resource utilization and prevent unnecessary interventions.
conclusionThis MR study found no genetic causality between psoriasis and renal impairment across three domains: static kidney function (eGFR, albuminuria), end-stage damage (CKD G3-G5, dialysis), and dynamic progression (CKDi25, Rapid3). These findings challenge prior observational associations and highlight the importance of considering psoriasis-independent pathways in renal risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.